Currently, the clinical management of patients with ERBB2-positive early breast cancer relies on clinical-pathological staging,17 with limited use of biomarkers for risk stratification besides ERBB2 status.18 De-escalation of adjuvant therapy is already a reality for most patients with stage I ERBB2-positive breast cancer. Here, ERBB2 is linked to breast carcinoma.